EMA Recommends Extending Indications for Decitabine / Cedazuridine By Ogkologos - May 29, 2026 132 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a combination with venetoclax for the treatment of adult patients with newly diagnosed AML Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR 120 years of discovery: 10 ways we’ve changed the story for... February 2, 2022 Prising open the trap: Getting to grips with targeted cancer drug... January 10, 2022 Hockey Fan Dubbed Hero After Saving Equipment Manager’s Life January 9, 2022 FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with... October 30, 2025 Load more HOT NEWS 10 Things About You That Change When You Lose Your Parents How My Cancer Diagnosis Has Fueled My Work in Improving Access... Ponatinib Effectively Treats Newly Diagnosed Acute Lymphoblastic Leukemia: The ASCO Plenary... ESMO Breast Cancer Congress 2022
